Metabolic-associated fatty liver disease is associated with low muscle mass and strength in patients with chronic hepatitis B
Cecy Maria de Lima Santos,Matheus Duarte Brito,Pedro Alves Soares Vaz de Castro,Thais Pontello de Vries,Nataly Lopes Viana,Marta Paula Pereira Coelho,Olívio Brito Malheiro,Tatiana Bering,Maria Cristina Gonzalez,Rosângela Teixeira,Rodrigo Dias Cambraia,Gifone Aguiar Rocha,Luciana Diniz Silva
DOI: https://doi.org/10.4254/wjh.v14.i8.1652
2022-08-26
World Journal of Hepatology
Abstract:BACKGROUND Although the prognostic relevance of sarcopenia has been increasingly recognised in the context of liver disease, there is a paucity of data evaluating body composition in patients with chronic hepatitis B (CHB). Beyond virus-related factors, nutritional and metabolic aspects can be associated with skeletal muscle abnormalities in these patients and should not be disregarded. AIM To evaluate the association between components of sarcopenia and demographic, clinical, lifestyle, nutritional, and biochemical variables in CHB patients. METHODS Dual-energy X-ray absorptiometry (DXA) was used to assess muscle mass by quantifying appendicular lean mass (ALM) adjusted for body mass index (ALM BMI ). Muscle function was evaluated by hand grip strength (HGS) and the timed up and go test. Metabolic-associated fatty liver disease (MAFLD) was defined according to the criteria proposed by an international expert panel. A body shape index and the International Physical Activity Questionnaire were used to assess central obesity and physical activity level, respectively. RESULTS This cross-sectional study included 105 CHB outpatients followed at the tertiary care ambulatory centre (mean age, 48.5 ± 12.0 years; 58.1% males; 76.2% without cirrhosis; 23.8% with compensated cirrhosis). The DXA-derived fat mass percentage was inversely correlated with the ALM BMI ( r = - 0.87) and HGS ( r = - 0.63). In the multivariable analysis, MAFLD, sedentarism and central obesity were positively and independently associated with low ALM BMI . MAFLD and central obesity were independently associated with low HGS. CONCLUSION MAFLD and central obesity were associated with low muscle mass and strength in patients with chronic hepatitis B, independent of the liver disease stage. Key Words: Chronic hepatitis B, Appendicular lean mass, Muscle strength, Metabolic associated fatty liver disease, Central obesity, Physical performance Core Tip: Recently, the clinical significance of sarcopenia in hepatic disease has been increasingly recognised. In patients with chronic hepatitis B, metabolic-associated fatty liver disease and central obesity were associated with low muscle mass and strength. Metabolic and skeletal muscle abnormality appraisal should be encouraged among individuals chronically infected with hepatitis B virus. Citation: Santos CML, Brito MD, Castro PASV, Vries TP, Viana NL, Coelho MPP, Malheiro OB, Bering T, Gonzalez MC, Teixeira R, Cambraia RD, Rocha GA, Silva LD. Metabolic-associated fatty liver disease is associated with low muscle mass and strength in patients with chronic hepatitis B. World J Hepatol 2022; 14(8): 1652-1666 URL: https://www.wjgnet.com/1948-5182/full/v14/i8/1652.htm DOI: https://dx.doi.org/10.4254/wjh.v14.i8.1652